<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433340</url>
  </required_header>
  <id_info>
    <org_study_id>M12-965</org_study_id>
    <secondary_id>2014-001471-31</secondary_id>
    <nct_id>NCT02433340</nct_id>
  </id_info>
  <brief_title>Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study</brief_title>
  <official_title>Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, 24-week OLE study to assess the safety and tolerability of
      ABT-122 in participants with rheumatoid arthritis (RA) who had had an inadequate response to
      methotrexate (MTX) therapy and who completed the preceding Study M12-963 randomized
      controlled trial, in which participants had been randomized to receive 1 of 3 doses of
      ABT-122 (60 mg every other week [EOW], 120 mg EOW, or 120 mg every week [EW]) or adalimumab
      40 mg EOW given on background methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American College of Rheumatology (ACR) 20 Response Rate at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hsCRP). Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20 Response Rate at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20 Response Rate at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20 Response Rate at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20 Response Rate at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20 Response Rate at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20 Response Rate at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20 Response Rate at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20 Response Rate at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20 Response Rate at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR20 Response Rate at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 Response Rate at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 Response Rate at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 Response Rate at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 Response Rate at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 Response Rate at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 Response Rate at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 Response Rate at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 Response Rate at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 Response Rate at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 Response Rate at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR50 Response Rate at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR70 Response Rate at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR70 Response Rate at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR70 Response Rate at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR70 Response Rate at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR70 Response Rate at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR70 Response Rate at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR70 Response Rate at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR70 Response Rate at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR70 Response Rate at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR70 Response Rate at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR70 Response Rate at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation, and Deaths</measure>
    <time_frame>from the first dose of study drug in study M12-965 until 70 days after the last dose of study drug (up to 32 weeks)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. An SAE is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Tender Joint Count (TJC68) at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC68 at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC68 at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC68 at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC68 at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC68 at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC68 at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC68 at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC68 at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC68 at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC68 at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Swollen Joint Count (SJC66) at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC66 at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC66 at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC66 at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC66 at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC66 at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC66 at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC66 at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC66 at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC66 at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC66 at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain visual analogue scale (VAS). The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 - 3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  -0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 - 3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  -0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 - 3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  -0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 - 3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  -0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 - 3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  -0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 - 3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  -0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 - 3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  -0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 - 3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  -0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 - 3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  -0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 - 3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  -0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0 - 3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  -0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score 28 (DAS28[hsCRP]) at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 (hsCRP) at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 (hsCRP) at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 (hsCRP) at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 (hsCRP) at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 (hsCRP) at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 (hsCRP) at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 (hsCRP) at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 (hsCRP) at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 (hsCRP) at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 (hsCRP) at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of Tender Joint Count 28 (TJC28) and Swollen Joint Count 28 (SJC28), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Disease Activity (LDA) or Clinical Remission (CR) Response Rate Per DAS28 (hsCRP) at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per DAS28 (hsCRP) at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per DAS28 (hsCRP) at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per DAS28 (hsCRP) at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per DAS28 (hsCRP) at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per DAS28 (hsCRP) at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per DAS28 (hsCRP) at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per DAS28 (hsCRP) at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per DAS28 (hsCRP) at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per DAS28 (hsCRP) at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per DAS28 (hsCRP) at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per DAS28 (hsCRP) at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per CDAI at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per CDAI at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per CDAI at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per CDAI at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per CDAI at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per CDAI at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per CDAI at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per CDAI at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per CDAI at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per CDAI at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDA or CR Response Rate Per CDAI at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per CDAI Criteria at Week 2</measure>
    <time_frame>Week 2 of Study M12-963</time_frame>
    <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per CDAI Criteria at Week 4</measure>
    <time_frame>Week 4 of Study M12-963</time_frame>
    <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per CDAI Criteria at Week 6</measure>
    <time_frame>Week 6 of Study M12-963</time_frame>
    <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per CDAI Criteria at Week 8</measure>
    <time_frame>Week 8 of Study M12-963</time_frame>
    <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per CDAI Criteria at Week 12</measure>
    <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per CDAI Criteria at Week 16</measure>
    <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per CDAI Criteria at Week 20</measure>
    <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per CDAI Criteria at Week 24</measure>
    <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per CDAI Criteria at Week 28</measure>
    <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per CDAI Criteria at Week 32</measure>
    <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Response Rate Per CDAI Criteria at Week 36</measure>
    <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
    <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ABT-122 120 mg EOW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receive open-label ABT-122 120 mg EOW subcutaneously, with the first dose administered at the last visit of Study M12-963 randomized controlled trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-122</intervention_name>
    <arm_group_label>ABT-122 120 mg EOW</arm_group_label>
    <other_name>Remtolumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subjects who have completed the preceding Study M12-963 (ABT-122)
        randomized controlled study and have not developed any discontinuation criteria, as defined
        in Study M12-963.

          -  If female, subject must meet one of the following criteria:

               1. Postmenopausal (defined as no menses for at least 1 year).

               2. Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or
                  hysterectomy).

               3. Practicing appropriate birth control, from the time of enrollment in this study
                  until at least 150 days after the last dose of study drug.

          -  Male who agrees to follow one of the protocol-specified pregnancy avoidance measures,
             including refraining from donating sperm, for up to 150 days post last dose of study
             drug.

          -  Subjects must voluntarily sign and date an informed consent, approved by an
             Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the
             initiation of any screening or study-specific procedures.

          -  Subject is judged to be in good health as determined by the Investigator based on the
             results of medical history, physical examination and laboratory profile performed.

        Exclusion Criteria: - Pregnant or breastfeeding female.

          -  Ongoing infections at Day 1 (Week 0) that have NOT been successfully treated within 14
             days.

          -  Anticipated requirement or receipt of any live vaccine during study participation
             including up to 120 days after the last dose of study drug.

          -  Current enrollment in another investigational study; with the exception of Study
             M12-963, which is required.

          -  Consideration by the Investigator, for any reason, that the subject is an unsuitable
             candidate to receive ABT-122.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Peloso, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <results_first_submitted>May 19, 2017</results_first_submitted>
  <results_first_submitted_qc>May 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2017</results_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolerability</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 158 participants (98% of those eligible) diagnosed with active rheumatoid arthritis (RA) on background methotrexate who had participated in the randomized controlled trial M12-963 (NCT02141997) enrolled in this open-label extension. Results include analyses of data for these participants from time points during M12-963, per protocol.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
          <description>Double-blind Adalimumab (ADA) 40 mg every other week (EOW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
        <group group_id="P2">
          <title>ABT-122 60 mg EOW / 120 mg EOW</title>
          <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
        <group group_id="P3">
          <title>ABT-122 120 mg EOW / 120 mg EOW</title>
          <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
        <group group_id="P4">
          <title>ABT-122 120 mg EW / 120 mg EOW</title>
          <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required Alternative/Prohibited Therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
          <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
        <group group_id="B2">
          <title>ABT-122 60 mg EOW / 120 mg EOW</title>
          <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
        <group group_id="B3">
          <title>ABT-122 120 mg EOW / 120 mg EOW</title>
          <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
        <group group_id="B4">
          <title>ABT-122 120 mg EW / 120 mg EOW</title>
          <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="158"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>American College of Rheumatology (ACR) 20 Response Rate at Week 2</title>
        <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hsCRP). Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. Last observation carried forward (LOCF) was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology (ACR) 20 Response Rate at Week 2</title>
          <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in tender joint count (TJC68), swollen joint count (SJC66), and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, patient's global assessment of disease activity (PtGA); physician's global assessment of disease activity (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), and high-sensitivity C-reactive protein (hsCRP). Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. Last observation carried forward (LOCF) was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" lower_limit="30.7" upper_limit="60.2"/>
                    <measurement group_id="O2" value="43.2" lower_limit="28.7" upper_limit="59.1"/>
                    <measurement group_id="O3" value="46.2" lower_limit="31.6" upper_limit="61.4"/>
                    <measurement group_id="O4" value="47.4" lower_limit="32.5" upper_limit="62.7"/>
                    <measurement group_id="O5" value="45.5" lower_limit="37.8" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response Rate at Week 4</title>
        <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response Rate at Week 4</title>
          <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="35.5" upper_limit="64.5"/>
                    <measurement group_id="O2" value="64.9" lower_limit="48.7" upper_limit="78.2"/>
                    <measurement group_id="O3" value="46.2" lower_limit="31.6" upper_limit="61.4"/>
                    <measurement group_id="O4" value="74.4" lower_limit="58.8" upper_limit="85.6"/>
                    <measurement group_id="O5" value="58.6" lower_limit="50.8" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response Rate at Week 6</title>
        <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response Rate at Week 6</title>
          <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="51.5" upper_limit="79.1"/>
                    <measurement group_id="O2" value="70.3" lower_limit="54.1" upper_limit="82.6"/>
                    <measurement group_id="O3" value="66.7" lower_limit="50.9" upper_limit="79.4"/>
                    <measurement group_id="O4" value="79.5" lower_limit="64.2" upper_limit="89.5"/>
                    <measurement group_id="O5" value="70.7" lower_limit="63.1" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response Rate at Week 8</title>
        <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response Rate at Week 8</title>
          <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" lower_limit="61.3" upper_limit="86.7"/>
                    <measurement group_id="O2" value="75.7" lower_limit="59.7" upper_limit="86.8"/>
                    <measurement group_id="O3" value="69.2" lower_limit="53.5" upper_limit="81.5"/>
                    <measurement group_id="O4" value="80.0" lower_limit="65.0" upper_limit="89.8"/>
                    <measurement group_id="O5" value="75.3" lower_limit="68.0" upper_limit="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response Rate at Week 12</title>
        <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response Rate at Week 12</title>
          <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" lower_limit="63.8" upper_limit="88.5"/>
                    <measurement group_id="O2" value="70.3" lower_limit="54.1" upper_limit="82.6"/>
                    <measurement group_id="O3" value="84.6" lower_limit="69.9" upper_limit="93.1"/>
                    <measurement group_id="O4" value="82.5" lower_limit="67.7" upper_limit="91.6"/>
                    <measurement group_id="O5" value="79.1" lower_limit="72.1" upper_limit="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response Rate at Week 16</title>
        <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response Rate at Week 16</title>
          <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="71.2" upper_limit="93.5"/>
                    <measurement group_id="O2" value="77.8" lower_limit="61.7" upper_limit="88.5"/>
                    <measurement group_id="O3" value="86.5" lower_limit="71.5" upper_limit="94.6"/>
                    <measurement group_id="O4" value="77.5" lower_limit="62.3" upper_limit="87.9"/>
                    <measurement group_id="O5" value="81.8" lower_limit="74.9" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response Rate at Week 20</title>
        <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response Rate at Week 20</title>
          <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="56.3" upper_limit="82.9"/>
                    <measurement group_id="O2" value="77.8" lower_limit="61.7" upper_limit="88.5"/>
                    <measurement group_id="O3" value="82.1" lower_limit="67.0" upper_limit="91.3"/>
                    <measurement group_id="O4" value="79.5" lower_limit="64.2" upper_limit="89.5"/>
                    <measurement group_id="O5" value="77.6" lower_limit="70.4" upper_limit="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response Rate at Week 24</title>
        <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response Rate at Week 24</title>
          <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" lower_limit="63.8" upper_limit="88.5"/>
                    <measurement group_id="O2" value="77.8" lower_limit="61.7" upper_limit="88.5"/>
                    <measurement group_id="O3" value="76.9" lower_limit="61.5" upper_limit="87.6"/>
                    <measurement group_id="O4" value="84.6" lower_limit="69.9" upper_limit="93.1"/>
                    <measurement group_id="O5" value="79.5" lower_limit="72.4" upper_limit="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response Rate at Week 28</title>
        <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response Rate at Week 28</title>
          <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="58.8" upper_limit="84.8"/>
                    <measurement group_id="O2" value="75.0" lower_limit="58.7" upper_limit="86.4"/>
                    <measurement group_id="O3" value="74.4" lower_limit="58.8" upper_limit="85.6"/>
                    <measurement group_id="O4" value="82.1" lower_limit="67.0" upper_limit="91.3"/>
                    <measurement group_id="O5" value="76.3" lower_limit="69.0" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response Rate at Week 32</title>
        <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response Rate at Week 32</title>
          <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" lower_limit="61.3" upper_limit="86.7"/>
                    <measurement group_id="O2" value="72.2" lower_limit="55.9" upper_limit="84.3"/>
                    <measurement group_id="O3" value="79.5" lower_limit="64.2" upper_limit="89.5"/>
                    <measurement group_id="O4" value="80.0" lower_limit="65.0" upper_limit="89.8"/>
                    <measurement group_id="O5" value="77.1" lower_limit="69.9" upper_limit="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response Rate at Week 36</title>
        <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response Rate at Week 36</title>
          <description>Percentage of participants with an ACR20 response, defined as at least 20% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="56.3" upper_limit="82.9"/>
                    <measurement group_id="O2" value="72.2" lower_limit="55.9" upper_limit="84.3"/>
                    <measurement group_id="O3" value="84.6" lower_limit="69.9" upper_limit="93.1"/>
                    <measurement group_id="O4" value="85.0" lower_limit="70.5" upper_limit="93.3"/>
                    <measurement group_id="O5" value="78.3" lower_limit="71.2" upper_limit="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR50 Response Rate at Week 2</title>
        <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response Rate at Week 2</title>
          <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="3.4" upper_limit="23.6"/>
                    <measurement group_id="O2" value="8.1" lower_limit="2.1" upper_limit="22.0"/>
                    <measurement group_id="O3" value="20.5" lower_limit="10.5" upper_limit="35.8"/>
                    <measurement group_id="O4" value="23.1" lower_limit="12.4" upper_limit="38.5"/>
                    <measurement group_id="O5" value="15.5" lower_limit="10.6" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR50 Response Rate at Week 4</title>
        <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response Rate at Week 4</title>
          <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="6.3" upper_limit="28.2"/>
                    <measurement group_id="O2" value="29.7" lower_limit="17.4" upper_limit="45.9"/>
                    <measurement group_id="O3" value="23.1" lower_limit="12.4" upper_limit="38.5"/>
                    <measurement group_id="O4" value="35.9" lower_limit="22.7" upper_limit="51.6"/>
                    <measurement group_id="O5" value="25.5" lower_limit="19.3" upper_limit="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR50 Response Rate at Week 6</title>
        <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response Rate at Week 6</title>
          <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="20.9" upper_limit="48.5"/>
                    <measurement group_id="O2" value="35.1" lower_limit="21.8" upper_limit="51.3"/>
                    <measurement group_id="O3" value="38.5" lower_limit="24.9" upper_limit="54.1"/>
                    <measurement group_id="O4" value="42.5" lower_limit="28.5" upper_limit="57.8"/>
                    <measurement group_id="O5" value="37.3" lower_limit="30.2" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR50 Response Rate at Week 8</title>
        <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response Rate at Week 8</title>
          <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="31.2" upper_limit="60.1"/>
                    <measurement group_id="O2" value="29.7" lower_limit="17.4" upper_limit="45.9"/>
                    <measurement group_id="O3" value="41.0" lower_limit="27.1" upper_limit="56.6"/>
                    <measurement group_id="O4" value="42.5" lower_limit="28.5" upper_limit="57.8"/>
                    <measurement group_id="O5" value="39.9" lower_limit="32.6" upper_limit="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR50 Response Rate at Week 12</title>
        <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response Rate at Week 12</title>
          <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="37.7" upper_limit="66.6"/>
                    <measurement group_id="O2" value="37.8" lower_limit="24.0" upper_limit="53.9"/>
                    <measurement group_id="O3" value="51.3" lower_limit="36.2" upper_limit="66.1"/>
                    <measurement group_id="O4" value="46.2" lower_limit="31.6" upper_limit="61.4"/>
                    <measurement group_id="O5" value="47.1" lower_limit="39.5" upper_limit="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR50 Response Rate at Week 16</title>
        <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response Rate at Week 16</title>
          <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" lower_limit="23.5" upper_limit="51.9"/>
                    <measurement group_id="O2" value="51.4" lower_limit="35.6" upper_limit="67.0"/>
                    <measurement group_id="O3" value="56.8" lower_limit="40.9" upper_limit="71.3"/>
                    <measurement group_id="O4" value="56.4" lower_limit="41.0" upper_limit="70.7"/>
                    <measurement group_id="O5" value="50.0" lower_limit="42.1" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR50 Response Rate at Week 20</title>
        <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response Rate at Week 20</title>
          <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="29.1" upper_limit="57.8"/>
                    <measurement group_id="O2" value="52.8" lower_limit="37.0" upper_limit="68.0"/>
                    <measurement group_id="O3" value="51.3" lower_limit="36.2" upper_limit="66.1"/>
                    <measurement group_id="O4" value="52.5" lower_limit="37.5" upper_limit="67.1"/>
                    <measurement group_id="O5" value="49.7" lower_limit="42.0" upper_limit="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR50 Response Rate at Week 24</title>
        <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response Rate at Week 24</title>
          <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="27.0" upper_limit="55.5"/>
                    <measurement group_id="O2" value="47.2" lower_limit="32.0" upper_limit="63.0"/>
                    <measurement group_id="O3" value="53.8" lower_limit="38.6" upper_limit="68.4"/>
                    <measurement group_id="O4" value="71.8" lower_limit="56.1" upper_limit="83.6"/>
                    <measurement group_id="O5" value="53.2" lower_limit="45.4" upper_limit="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR50 Response Rate at Week 28</title>
        <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response Rate at Week 28</title>
          <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="35.5" upper_limit="64.5"/>
                    <measurement group_id="O2" value="47.2" lower_limit="32.0" upper_limit="63.0"/>
                    <measurement group_id="O3" value="51.3" lower_limit="36.2" upper_limit="66.1"/>
                    <measurement group_id="O4" value="69.2" lower_limit="53.5" upper_limit="81.5"/>
                    <measurement group_id="O5" value="54.5" lower_limit="46.7" upper_limit="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR50 Response Rate at Week 32</title>
        <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response Rate at Week 32</title>
          <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="31.2" upper_limit="60.1"/>
                    <measurement group_id="O2" value="58.3" lower_limit="42.2" upper_limit="72.9"/>
                    <measurement group_id="O3" value="51.3" lower_limit="36.2" upper_limit="66.1"/>
                    <measurement group_id="O4" value="62.5" lower_limit="47.0" upper_limit="75.8"/>
                    <measurement group_id="O5" value="54.1" lower_limit="46.3" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR50 Response Rate at Week 36</title>
        <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response Rate at Week 36</title>
          <description>Percentage of participants with an ACR50 response, defined as at least 50% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="31.2" upper_limit="60.1"/>
                    <measurement group_id="O2" value="50.0" lower_limit="34.5" upper_limit="65.5"/>
                    <measurement group_id="O3" value="53.8" lower_limit="38.6" upper_limit="68.4"/>
                    <measurement group_id="O4" value="62.5" lower_limit="47.0" upper_limit="75.8"/>
                    <measurement group_id="O5" value="52.9" lower_limit="45.1" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR70 Response Rate at Week 2</title>
        <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response Rate at Week 2</title>
          <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="10.4"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.0" upper_limit="15.1"/>
                    <measurement group_id="O3" value="5.1" lower_limit="0.5" upper_limit="17.8"/>
                    <measurement group_id="O4" value="5.1" lower_limit="0.5" upper_limit="17.8"/>
                    <measurement group_id="O5" value="3.2" lower_limit="1.2" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR70 Response Rate at Week 4</title>
        <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response Rate at Week 4</title>
          <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="0.5" upper_limit="16.6"/>
                    <measurement group_id="O2" value="10.8" lower_limit="3.7" upper_limit="25.3"/>
                    <measurement group_id="O3" value="10.3" lower_limit="3.5" upper_limit="24.2"/>
                    <measurement group_id="O4" value="17.5" lower_limit="8.4" upper_limit="32.3"/>
                    <measurement group_id="O5" value="10.8" lower_limit="6.7" upper_limit="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR70 Response Rate at Week 6</title>
        <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response Rate at Week 6</title>
          <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="8.0" upper_limit="30.9"/>
                    <measurement group_id="O2" value="13.5" lower_limit="5.4" upper_limit="28.5"/>
                    <measurement group_id="O3" value="17.9" lower_limit="8.7" upper_limit="33.0"/>
                    <measurement group_id="O4" value="20.0" lower_limit="10.2" upper_limit="35.0"/>
                    <measurement group_id="O5" value="17.1" lower_limit="12.0" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR70 Response Rate at Week 8</title>
        <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response Rate at Week 8</title>
          <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="9.7" upper_limit="33.6"/>
                    <measurement group_id="O2" value="8.1" lower_limit="2.1" upper_limit="22.0"/>
                    <measurement group_id="O3" value="25.6" lower_limit="14.4" upper_limit="41.2"/>
                    <measurement group_id="O4" value="27.5" lower_limit="16.0" upper_limit="43.0"/>
                    <measurement group_id="O5" value="20.3" lower_limit="14.7" upper_limit="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR70 Response Rate at Week 12</title>
        <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response Rate at Week 12</title>
          <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="13.3" upper_limit="38.7"/>
                    <measurement group_id="O2" value="24.3" lower_limit="13.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="20.5" lower_limit="10.5" upper_limit="35.8"/>
                    <measurement group_id="O4" value="35.0" lower_limit="22.1" upper_limit="50.5"/>
                    <measurement group_id="O5" value="25.9" lower_limit="19.7" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR70 Response Rate at Week 16</title>
        <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response Rate at Week 16</title>
          <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="6.7" upper_limit="29.5"/>
                    <measurement group_id="O2" value="30.6" lower_limit="17.9" upper_limit="47.0"/>
                    <measurement group_id="O3" value="33.3" lower_limit="20.1" upper_limit="49.7"/>
                    <measurement group_id="O4" value="25.6" lower_limit="14.4" upper_limit="41.2"/>
                    <measurement group_id="O5" value="25.8" lower_limit="19.5" upper_limit="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR70 Response Rate at Week 20</title>
        <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response Rate at Week 20</title>
          <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="9.7" upper_limit="33.6"/>
                    <measurement group_id="O2" value="31.4" lower_limit="18.4" upper_limit="48.1"/>
                    <measurement group_id="O3" value="33.3" lower_limit="20.6" upper_limit="49.1"/>
                    <measurement group_id="O4" value="32.5" lower_limit="20.0" upper_limit="48.1"/>
                    <measurement group_id="O5" value="28.8" lower_limit="22.3" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR70 Response Rate at Week 24</title>
        <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response Rate at Week 24</title>
          <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="9.7" upper_limit="33.6"/>
                    <measurement group_id="O2" value="25.0" lower_limit="13.6" upper_limit="41.3"/>
                    <measurement group_id="O3" value="28.2" lower_limit="16.4" upper_limit="43.9"/>
                    <measurement group_id="O4" value="40.0" lower_limit="26.3" upper_limit="55.4"/>
                    <measurement group_id="O5" value="28.0" lower_limit="21.6" upper_limit="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR70 Response Rate at Week 28</title>
        <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response Rate at Week 28</title>
          <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="8.0" upper_limit="30.9"/>
                    <measurement group_id="O2" value="27.8" lower_limit="15.7" upper_limit="44.1"/>
                    <measurement group_id="O3" value="30.8" lower_limit="18.5" upper_limit="46.5"/>
                    <measurement group_id="O4" value="41.0" lower_limit="27.1" upper_limit="56.6"/>
                    <measurement group_id="O5" value="28.8" lower_limit="22.3" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR70 Response Rate at Week 32</title>
        <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response Rate at Week 32</title>
          <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="8.0" upper_limit="30.9"/>
                    <measurement group_id="O2" value="27.8" lower_limit="15.7" upper_limit="44.1"/>
                    <measurement group_id="O3" value="23.1" lower_limit="12.4" upper_limit="38.5"/>
                    <measurement group_id="O4" value="42.5" lower_limit="28.5" upper_limit="57.8"/>
                    <measurement group_id="O5" value="27.4" lower_limit="21.0" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR70 Response Rate at Week 36</title>
        <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response Rate at Week 36</title>
          <description>Percentage of participants with an ACR70 response, defined as at least 70% reduction (improvement) compared with baseline in TJC68, SJC66, and at least 3 of the 5 remaining ACR core set measures: patient's assessment of pain, PtGA; PGA, HAQ-DI, and hsCRP. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="13.3" upper_limit="38.7"/>
                    <measurement group_id="O2" value="30.6" lower_limit="17.9" upper_limit="47.0"/>
                    <measurement group_id="O3" value="35.9" lower_limit="22.7" upper_limit="51.6"/>
                    <measurement group_id="O4" value="45.0" lower_limit="30.7" upper_limit="60.2"/>
                    <measurement group_id="O5" value="33.8" lower_limit="26.8" upper_limit="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation, and Deaths</title>
        <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. An SAE is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.</description>
        <time_frame>from the first dose of study drug in study M12-965 until 70 days after the last dose of study drug (up to 32 weeks)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation, and Deaths</title>
          <description>An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. An SAE is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE possibly study drug-related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE possibly study drug-related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to study drug discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (includes non-treatment-emergent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline In Tender Joint Count (TJC68) at Week 2</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Tender Joint Count (TJC68) at Week 2</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="10.28"/>
                    <measurement group_id="O2" value="-11.6" spread="10.57"/>
                    <measurement group_id="O3" value="-11.0" spread="11.12"/>
                    <measurement group_id="O4" value="-12.9" spread="13.84"/>
                    <measurement group_id="O5" value="-11.2" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC68 at Week 4</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC68 at Week 4</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="9.98"/>
                    <measurement group_id="O2" value="-16.6" spread="12.48"/>
                    <measurement group_id="O3" value="-13.6" spread="12.00"/>
                    <measurement group_id="O4" value="-16.1" spread="12.77"/>
                    <measurement group_id="O5" value="-14.8" spread="11.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC68 at Week 6</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC68 at Week 6</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" spread="10.18"/>
                    <measurement group_id="O2" value="-16.9" spread="11.67"/>
                    <measurement group_id="O3" value="-15.3" spread="11.05"/>
                    <measurement group_id="O4" value="-16.6" spread="12.56"/>
                    <measurement group_id="O5" value="-16.1" spread="11.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC68 at Week 8</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC68 at Week 8</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" spread="9.93"/>
                    <measurement group_id="O2" value="-17.4" spread="10.85"/>
                    <measurement group_id="O3" value="-17.1" spread="10.21"/>
                    <measurement group_id="O4" value="-17.1" spread="13.33"/>
                    <measurement group_id="O5" value="-17.2" spread="11.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC68 at Week 12</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC68 at Week 12</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.4" spread="11.78"/>
                    <measurement group_id="O2" value="-16.9" spread="10.90"/>
                    <measurement group_id="O3" value="-18.6" spread="10.16"/>
                    <measurement group_id="O4" value="-18.0" spread="12.64"/>
                    <measurement group_id="O5" value="-18.0" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC68 at Week 16</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC68 at Week 16</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" spread="12.03"/>
                    <measurement group_id="O2" value="-19.2" spread="10.57"/>
                    <measurement group_id="O3" value="-17.6" spread="9.14"/>
                    <measurement group_id="O4" value="-18.1" spread="12.38"/>
                    <measurement group_id="O5" value="-18.3" spread="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC68 at Week 20</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC68 at Week 20</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.6" spread="11.93"/>
                    <measurement group_id="O2" value="-19.7" spread="10.60"/>
                    <measurement group_id="O3" value="-17.8" spread="10.31"/>
                    <measurement group_id="O4" value="-19.0" spread="11.89"/>
                    <measurement group_id="O5" value="-18.5" spread="11.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC68 at Week 24</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC68 at Week 24</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.3" spread="12.16"/>
                    <measurement group_id="O2" value="-18.3" spread="10.27"/>
                    <measurement group_id="O3" value="-17.4" spread="9.70"/>
                    <measurement group_id="O4" value="-19.8" spread="12.32"/>
                    <measurement group_id="O5" value="-18.7" spread="11.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC68 at Week 28</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC68 at Week 28</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.2" spread="10.88"/>
                    <measurement group_id="O2" value="-18.9" spread="12.26"/>
                    <measurement group_id="O3" value="-17.9" spread="10.31"/>
                    <measurement group_id="O4" value="-21.0" spread="13.02"/>
                    <measurement group_id="O5" value="-19.0" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC68 at Week 32</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC68 at Week 32</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.2" spread="11.72"/>
                    <measurement group_id="O2" value="-19.7" spread="11.04"/>
                    <measurement group_id="O3" value="-17.9" spread="10.47"/>
                    <measurement group_id="O4" value="-20.3" spread="13.38"/>
                    <measurement group_id="O5" value="-19.0" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC68 at Week 36</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC68 at Week 36</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was &quot;tender or painful&quot; where presence of tenderness was scored as &quot;1&quot; and the absence of tenderness was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total TJC68, which is based on 68 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for TJC68 was 0 to 68, with a higher score indication a greater degree of tenderness. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.2" spread="10.92"/>
                    <measurement group_id="O2" value="-18.5" spread="11.92"/>
                    <measurement group_id="O3" value="-17.7" spread="10.06"/>
                    <measurement group_id="O4" value="-20.3" spread="12.88"/>
                    <measurement group_id="O5" value="-18.7" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Swollen Joint Count (SJC66) at Week 2</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joint Count (SJC66) at Week 2</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="9.07"/>
                    <measurement group_id="O2" value="-8.8" spread="8.50"/>
                    <measurement group_id="O3" value="-8.6" spread="10.84"/>
                    <measurement group_id="O4" value="-10.8" spread="9.34"/>
                    <measurement group_id="O5" value="-9.0" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC66 at Week 4</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC66 at Week 4</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="8.72"/>
                    <measurement group_id="O2" value="-10.6" spread="8.04"/>
                    <measurement group_id="O3" value="-10.3" spread="10.50"/>
                    <measurement group_id="O4" value="-13.3" spread="9.29"/>
                    <measurement group_id="O5" value="-10.7" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC66 at Week 6</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC66 at Week 6</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="8.09"/>
                    <measurement group_id="O2" value="-11.9" spread="7.71"/>
                    <measurement group_id="O3" value="-12.3" spread="10.15"/>
                    <measurement group_id="O4" value="-13.3" spread="9.31"/>
                    <measurement group_id="O5" value="-12.3" spread="8.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC66 at Week 8</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC66 at Week 8</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="8.26"/>
                    <measurement group_id="O2" value="-12.4" spread="7.76"/>
                    <measurement group_id="O3" value="-13.8" spread="9.32"/>
                    <measurement group_id="O4" value="-14.3" spread="9.43"/>
                    <measurement group_id="O5" value="-13.2" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC66 at Week 12</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC66 at Week 12</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="8.73"/>
                    <measurement group_id="O2" value="-11.8" spread="9.51"/>
                    <measurement group_id="O3" value="-13.4" spread="9.13"/>
                    <measurement group_id="O4" value="-14.8" spread="9.00"/>
                    <measurement group_id="O5" value="-13.2" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC66 at Week 16</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC66 at Week 16</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" spread="8.50"/>
                    <measurement group_id="O2" value="-13.5" spread="9.60"/>
                    <measurement group_id="O3" value="-13.8" spread="8.90"/>
                    <measurement group_id="O4" value="-14.5" spread="8.69"/>
                    <measurement group_id="O5" value="-13.7" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC66 at Week 20</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC66 at Week 20</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="7.47"/>
                    <measurement group_id="O2" value="-14.6" spread="8.97"/>
                    <measurement group_id="O3" value="-13.8" spread="10.30"/>
                    <measurement group_id="O4" value="-15.4" spread="8.95"/>
                    <measurement group_id="O5" value="-14.0" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC66 at Week 24</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC66 at Week 24</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" spread="8.21"/>
                    <measurement group_id="O2" value="-13.8" spread="8.68"/>
                    <measurement group_id="O3" value="-14.6" spread="9.87"/>
                    <measurement group_id="O4" value="-15.6" spread="9.16"/>
                    <measurement group_id="O5" value="-14.5" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC66 at Week 28</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC66 at Week 28</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="6.88"/>
                    <measurement group_id="O2" value="-14.0" spread="10.12"/>
                    <measurement group_id="O3" value="-14.9" spread="9.49"/>
                    <measurement group_id="O4" value="-15.8" spread="9.29"/>
                    <measurement group_id="O5" value="-14.5" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC66 at Week 32</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC66 at Week 32</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="8.14"/>
                    <measurement group_id="O2" value="-13.9" spread="10.34"/>
                    <measurement group_id="O3" value="-14.3" spread="9.81"/>
                    <measurement group_id="O4" value="-14.9" spread="9.71"/>
                    <measurement group_id="O5" value="-14.1" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC66 at Week 36</title>
        <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC66 at Week 36</title>
          <description>At each study visit, a joint evaluator assessed whether a particular joint was swollen where presence of swelling was scored as &quot;1&quot; and the absence of swelling was scored as &quot;0,&quot; provided the joint was not replaced or could not be assessed due to other reasons. The total SJC66, which is based on 66 joints, was derived as the sum of all &quot;1s&quot; thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 was 0 to 66, with a higher score indicating a greater degree of swelling. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="7.76"/>
                    <measurement group_id="O2" value="-14.0" spread="10.55"/>
                    <measurement group_id="O3" value="-15.0" spread="9.57"/>
                    <measurement group_id="O4" value="-14.8" spread="9.82"/>
                    <measurement group_id="O5" value="-14.0" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 2</title>
        <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain visual analogue scale (VAS). The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had a baseline and post-baseline assessment. LOCF was used for missing data; LOCF imputation was conducted separately for M12-963 and M12-965 (ie, data from M12-963 was not carried forward to visits in M12-965).</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 2</title>
          <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain visual analogue scale (VAS). The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had a baseline and post-baseline assessment. LOCF was used for missing data; LOCF imputation was conducted separately for M12-963 and M12-965 (ie, data from M12-963 was not carried forward to visits in M12-965).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.9" spread="22.82"/>
                    <measurement group_id="O2" value="-20.1" spread="16.83"/>
                    <measurement group_id="O3" value="-22.4" spread="23.49"/>
                    <measurement group_id="O4" value="-22.3" spread="22.46"/>
                    <measurement group_id="O5" value="-20.7" spread="21.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 4</title>
        <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 4</title>
          <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.5" spread="20.24"/>
                    <measurement group_id="O2" value="-28.7" spread="20.76"/>
                    <measurement group_id="O3" value="-24.8" spread="26.57"/>
                    <measurement group_id="O4" value="-29.3" spread="23.07"/>
                    <measurement group_id="O5" value="-26.8" spread="22.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 6</title>
        <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 6</title>
          <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.8" spread="21.24"/>
                    <measurement group_id="O2" value="-29.1" spread="22.48"/>
                    <measurement group_id="O3" value="-29.8" spread="27.07"/>
                    <measurement group_id="O4" value="-29.9" spread="21.36"/>
                    <measurement group_id="O5" value="-30.2" spread="22.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 8</title>
        <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 8</title>
          <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.5" spread="24.64"/>
                    <measurement group_id="O2" value="-29.8" spread="21.56"/>
                    <measurement group_id="O3" value="-30.2" spread="27.89"/>
                    <measurement group_id="O4" value="-36.0" spread="23.11"/>
                    <measurement group_id="O5" value="-31.7" spread="24.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 12</title>
        <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 12</title>
          <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.2" spread="19.91"/>
                    <measurement group_id="O2" value="-29.3" spread="22.34"/>
                    <measurement group_id="O3" value="-37.9" spread="27.18"/>
                    <measurement group_id="O4" value="-36.5" spread="23.52"/>
                    <measurement group_id="O5" value="-35.1" spread="23.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 16</title>
        <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 16</title>
          <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.9" spread="24.68"/>
                    <measurement group_id="O2" value="-33.0" spread="24.11"/>
                    <measurement group_id="O3" value="-35.0" spread="28.43"/>
                    <measurement group_id="O4" value="-38.5" spread="22.92"/>
                    <measurement group_id="O5" value="-34.6" spread="24.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 20</title>
        <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 20</title>
          <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.2" spread="22.48"/>
                    <measurement group_id="O2" value="-40.3" spread="24.12"/>
                    <measurement group_id="O3" value="-37.8" spread="28.78"/>
                    <measurement group_id="O4" value="-36.8" spread="21.72"/>
                    <measurement group_id="O5" value="-36.1" spread="24.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 24</title>
        <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 24</title>
          <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.7" spread="21.86"/>
                    <measurement group_id="O2" value="-35.9" spread="23.28"/>
                    <measurement group_id="O3" value="-32.0" spread="30.31"/>
                    <measurement group_id="O4" value="-39.4" spread="23.64"/>
                    <measurement group_id="O5" value="-34.7" spread="24.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 28</title>
        <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 28</title>
          <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" spread="22.39"/>
                    <measurement group_id="O2" value="-36.2" spread="28.88"/>
                    <measurement group_id="O3" value="-35.3" spread="28.64"/>
                    <measurement group_id="O4" value="-40.1" spread="22.61"/>
                    <measurement group_id="O5" value="-34.9" spread="25.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 32</title>
        <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 32</title>
          <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" spread="22.16"/>
                    <measurement group_id="O2" value="-37.4" spread="25.63"/>
                    <measurement group_id="O3" value="-34.3" spread="32.99"/>
                    <measurement group_id="O4" value="-42.8" spread="25.31"/>
                    <measurement group_id="O5" value="-35.3" spread="27.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Pain at Week 36</title>
        <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Pain at Week 36</title>
          <description>Participants assessed their pain in the previous week using a Patient's Global Assessment Pain VAS. The range is 0 to 100 mm with no pain being indicated by 0 and severe pain by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.3" spread="23.36"/>
                    <measurement group_id="O2" value="-36.1" spread="28.90"/>
                    <measurement group_id="O3" value="-39.3" spread="31.37"/>
                    <measurement group_id="O4" value="-41.8" spread="28.21"/>
                    <measurement group_id="O5" value="-37.0" spread="28.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 2</title>
        <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 2</title>
          <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.1" spread="23.77"/>
                    <measurement group_id="O2" value="-14.2" spread="16.41"/>
                    <measurement group_id="O3" value="-21.3" spread="19.92"/>
                    <measurement group_id="O4" value="-17.2" spread="23.06"/>
                    <measurement group_id="O5" value="-17.7" spread="21.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 4</title>
        <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 4</title>
          <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.6" spread="21.73"/>
                    <measurement group_id="O2" value="-25.6" spread="22.33"/>
                    <measurement group_id="O3" value="-20.7" spread="24.62"/>
                    <measurement group_id="O4" value="-26.6" spread="21.79"/>
                    <measurement group_id="O5" value="-23.3" spread="22.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 6</title>
        <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 6</title>
          <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.5" spread="20.97"/>
                    <measurement group_id="O2" value="-23.2" spread="22.21"/>
                    <measurement group_id="O3" value="-26.9" spread="24.17"/>
                    <measurement group_id="O4" value="-27.9" spread="21.14"/>
                    <measurement group_id="O5" value="-26.2" spread="21.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 8</title>
        <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 8</title>
          <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.1" spread="24.33"/>
                    <measurement group_id="O2" value="-26.8" spread="23.25"/>
                    <measurement group_id="O3" value="-31.8" spread="25.54"/>
                    <measurement group_id="O4" value="-34.1" spread="22.93"/>
                    <measurement group_id="O5" value="-30.0" spread="24.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 12</title>
        <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 12</title>
          <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.2" spread="23.39"/>
                    <measurement group_id="O2" value="-29.0" spread="25.11"/>
                    <measurement group_id="O3" value="-34.1" spread="21.41"/>
                    <measurement group_id="O4" value="-35.6" spread="25.62"/>
                    <measurement group_id="O5" value="-32.0" spread="23.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 16</title>
        <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 16</title>
          <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" spread="24.09"/>
                    <measurement group_id="O2" value="-29.3" spread="24.91"/>
                    <measurement group_id="O3" value="-34.8" spread="20.59"/>
                    <measurement group_id="O4" value="-35.8" spread="22.51"/>
                    <measurement group_id="O5" value="-31.6" spread="23.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 20</title>
        <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 20</title>
          <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" spread="20.98"/>
                    <measurement group_id="O2" value="-35.6" spread="24.56"/>
                    <measurement group_id="O3" value="-35.4" spread="26.44"/>
                    <measurement group_id="O4" value="-35.4" spread="22.95"/>
                    <measurement group_id="O5" value="-33.6" spread="23.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 24</title>
        <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 24</title>
          <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.5" spread="22.81"/>
                    <measurement group_id="O2" value="-33.1" spread="24.25"/>
                    <measurement group_id="O3" value="-32.7" spread="25.16"/>
                    <measurement group_id="O4" value="-38.9" spread="23.63"/>
                    <measurement group_id="O5" value="-34.0" spread="23.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 28</title>
        <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 28</title>
          <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.0" spread="23.25"/>
                    <measurement group_id="O2" value="-33.1" spread="27.93"/>
                    <measurement group_id="O3" value="-32.6" spread="27.33"/>
                    <measurement group_id="O4" value="-39.7" spread="25.57"/>
                    <measurement group_id="O5" value="-32.5" spread="26.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 32</title>
        <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 32</title>
          <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.4" spread="23.87"/>
                    <measurement group_id="O2" value="-34.2" spread="26.17"/>
                    <measurement group_id="O3" value="-32.8" spread="28.91"/>
                    <measurement group_id="O4" value="-43.8" spread="23.56"/>
                    <measurement group_id="O5" value="-34.5" spread="26.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 36</title>
        <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Disease Activity at Week 36</title>
          <description>Participants assessed their disease activity for the past 24 hours using a Patient's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.5" spread="26.04"/>
                    <measurement group_id="O2" value="-32.5" spread="26.16"/>
                    <measurement group_id="O3" value="-37.5" spread="25.73"/>
                    <measurement group_id="O4" value="-38.3" spread="29.65"/>
                    <measurement group_id="O5" value="-34.4" spread="26.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 2</title>
        <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 2</title>
          <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.5" spread="21.80"/>
                    <measurement group_id="O2" value="-25.8" spread="17.29"/>
                    <measurement group_id="O3" value="-29.5" spread="21.25"/>
                    <measurement group_id="O4" value="-26.5" spread="21.54"/>
                    <measurement group_id="O5" value="-26.6" spread="20.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 4</title>
        <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 4</title>
          <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6" spread="20.49"/>
                    <measurement group_id="O2" value="-35.5" spread="21.15"/>
                    <measurement group_id="O3" value="-34.5" spread="21.58"/>
                    <measurement group_id="O4" value="-37.3" spread="23.00"/>
                    <measurement group_id="O5" value="-33.8" spread="21.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 6</title>
        <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 6</title>
          <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.5" spread="18.77"/>
                    <measurement group_id="O2" value="-39.0" spread="22.76"/>
                    <measurement group_id="O3" value="-40.3" spread="23.63"/>
                    <measurement group_id="O4" value="-40.1" spread="20.94"/>
                    <measurement group_id="O5" value="-39.5" spread="21.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 8</title>
        <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 8</title>
          <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.0" spread="17.82"/>
                    <measurement group_id="O2" value="-39.6" spread="20.94"/>
                    <measurement group_id="O3" value="-45.6" spread="21.16"/>
                    <measurement group_id="O4" value="-43.4" spread="22.87"/>
                    <measurement group_id="O5" value="-42.4" spread="20.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 12</title>
        <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 12</title>
          <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.4" spread="20.30"/>
                    <measurement group_id="O2" value="-42.9" spread="20.90"/>
                    <measurement group_id="O3" value="-49.7" spread="20.54"/>
                    <measurement group_id="O4" value="-47.6" spread="19.86"/>
                    <measurement group_id="O5" value="-46.2" spread="20.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 16</title>
        <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 16</title>
          <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.0" spread="17.04"/>
                    <measurement group_id="O2" value="-45.3" spread="24.23"/>
                    <measurement group_id="O3" value="-47.3" spread="20.99"/>
                    <measurement group_id="O4" value="-47.3" spread="21.46"/>
                    <measurement group_id="O5" value="-46.4" spread="20.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 20</title>
        <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 20</title>
          <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.3" spread="19.08"/>
                    <measurement group_id="O2" value="-46.1" spread="20.28"/>
                    <measurement group_id="O3" value="-45.6" spread="22.89"/>
                    <measurement group_id="O4" value="-49.3" spread="21.64"/>
                    <measurement group_id="O5" value="-46.3" spread="20.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24</title>
        <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24</title>
          <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.8" spread="18.06"/>
                    <measurement group_id="O2" value="-46.7" spread="22.00"/>
                    <measurement group_id="O3" value="-47.4" spread="23.02"/>
                    <measurement group_id="O4" value="-49.9" spread="23.05"/>
                    <measurement group_id="O5" value="-47.4" spread="21.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 28</title>
        <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 28</title>
          <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.5" spread="20.72"/>
                    <measurement group_id="O2" value="-48.7" spread="22.19"/>
                    <measurement group_id="O3" value="-48.2" spread="22.85"/>
                    <measurement group_id="O4" value="-51.7" spread="20.85"/>
                    <measurement group_id="O5" value="-48.2" spread="21.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 32</title>
        <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 32</title>
          <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.2" spread="23.07"/>
                    <measurement group_id="O2" value="-50.0" spread="24.46"/>
                    <measurement group_id="O3" value="-49.9" spread="24.42"/>
                    <measurement group_id="O4" value="-51.7" spread="25.03"/>
                    <measurement group_id="O5" value="-49.1" spread="24.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 36</title>
        <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Disease Activity at Week 36</title>
          <description>The physician assessed the participant's disease activity at the time of visit using a Physician's Global Assessment of Disease VAS. The range is 0 to 100 mm with no activity being indicated by 0 and severe activity by 100. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.4" spread="23.72"/>
                    <measurement group_id="O2" value="-48.0" spread="23.10"/>
                    <measurement group_id="O3" value="-50.5" spread="24.55"/>
                    <measurement group_id="O4" value="-51.8" spread="24.24"/>
                    <measurement group_id="O5" value="-48.1" spread="23.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 2</title>
        <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 2</title>
          <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.486"/>
                    <measurement group_id="O2" value="-0.31" spread="0.463"/>
                    <measurement group_id="O3" value="-0.29" spread="0.481"/>
                    <measurement group_id="O4" value="-0.40" spread="0.538"/>
                    <measurement group_id="O5" value="-0.31" spread="0.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI at Week 4</title>
        <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI at Week 4</title>
          <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.552"/>
                    <measurement group_id="O2" value="-0.40" spread="0.580"/>
                    <measurement group_id="O3" value="-0.47" spread="0.625"/>
                    <measurement group_id="O4" value="-0.62" spread="0.711"/>
                    <measurement group_id="O5" value="-0.47" spread="0.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI at Week 6</title>
        <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI at Week 6</title>
          <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.601"/>
                    <measurement group_id="O2" value="-0.46" spread="0.607"/>
                    <measurement group_id="O3" value="-0.63" spread="0.711"/>
                    <measurement group_id="O4" value="-0.64" spread="0.584"/>
                    <measurement group_id="O5" value="-0.57" spread="0.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI at Week 8</title>
        <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI at Week 8</title>
          <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.619"/>
                    <measurement group_id="O2" value="-0.52" spread="0.525"/>
                    <measurement group_id="O3" value="-0.65" spread="0.648"/>
                    <measurement group_id="O4" value="-0.71" spread="0.711"/>
                    <measurement group_id="O5" value="-0.61" spread="0.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI at Week 12</title>
        <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI at Week 12</title>
          <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.654"/>
                    <measurement group_id="O2" value="-0.55" spread="0.611"/>
                    <measurement group_id="O3" value="-0.66" spread="0.701"/>
                    <measurement group_id="O4" value="-0.88" spread="0.677"/>
                    <measurement group_id="O5" value="-0.70" spread="0.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI at Week 16</title>
        <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI at Week 16</title>
          <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.616"/>
                    <measurement group_id="O2" value="-0.67" spread="0.631"/>
                    <measurement group_id="O3" value="-0.67" spread="0.689"/>
                    <measurement group_id="O4" value="-0.90" spread="0.649"/>
                    <measurement group_id="O5" value="-0.71" spread="0.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI at Week 20</title>
        <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI at Week 20</title>
          <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.662"/>
                    <measurement group_id="O2" value="-0.73" spread="0.555"/>
                    <measurement group_id="O3" value="-0.70" spread="0.788"/>
                    <measurement group_id="O4" value="-0.88" spread="0.690"/>
                    <measurement group_id="O5" value="-0.71" spread="0.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI at Week 24</title>
        <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI at Week 24</title>
          <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.604"/>
                    <measurement group_id="O2" value="-0.74" spread="0.617"/>
                    <measurement group_id="O3" value="-0.60" spread="0.805"/>
                    <measurement group_id="O4" value="-0.91" spread="0.704"/>
                    <measurement group_id="O5" value="-0.72" spread="0.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI at Week 28</title>
        <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI at Week 28</title>
          <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.600"/>
                    <measurement group_id="O2" value="-0.77" spread="0.630"/>
                    <measurement group_id="O3" value="-0.69" spread="0.727"/>
                    <measurement group_id="O4" value="-0.99" spread="0.699"/>
                    <measurement group_id="O5" value="-0.76" spread="0.676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI at Week 32</title>
        <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI at Week 32</title>
          <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.576"/>
                    <measurement group_id="O2" value="-0.76" spread="0.674"/>
                    <measurement group_id="O3" value="-0.66" spread="0.794"/>
                    <measurement group_id="O4" value="-0.91" spread="0.659"/>
                    <measurement group_id="O5" value="-0.71" spread="0.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI at Week 36</title>
        <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI at Week 36</title>
          <description>HAQ-DI is a self-reported participant outcome measurement. It is calculated as the mean of the scores from 8 following categories with a range 0  3: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The higher the score, the more likely to associate with morbidity and mortality for the participant. The minimum clinically important difference in HAQ-DI was defined as change from baseline  0.22. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.619"/>
                    <measurement group_id="O2" value="-0.73" spread="0.698"/>
                    <measurement group_id="O3" value="-0.71" spread="0.674"/>
                    <measurement group_id="O4" value="-0.81" spread="0.749"/>
                    <measurement group_id="O5" value="-0.72" spread="0.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 2</title>
        <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 2</title>
          <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="25.19"/>
                    <measurement group_id="O2" value="-9.9" spread="12.89"/>
                    <measurement group_id="O3" value="-12.6" spread="18.56"/>
                    <measurement group_id="O4" value="-14.9" spread="25.70"/>
                    <measurement group_id="O5" value="-12.5" spread="21.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP at Week 4</title>
        <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP at Week 4</title>
          <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="25.40"/>
                    <measurement group_id="O2" value="-8.0" spread="12.37"/>
                    <measurement group_id="O3" value="-11.7" spread="17.43"/>
                    <measurement group_id="O4" value="-14.6" spread="26.51"/>
                    <measurement group_id="O5" value="-12.0" spread="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP at Week 6</title>
        <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP at Week 6</title>
          <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="25.15"/>
                    <measurement group_id="O2" value="-8.0" spread="11.98"/>
                    <measurement group_id="O3" value="-10.7" spread="18.84"/>
                    <measurement group_id="O4" value="-14.9" spread="26.56"/>
                    <measurement group_id="O5" value="-11.8" spread="21.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP at Week 8</title>
        <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP at Week 8</title>
          <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="24.96"/>
                    <measurement group_id="O2" value="-8.0" spread="13.13"/>
                    <measurement group_id="O3" value="-10.7" spread="19.00"/>
                    <measurement group_id="O4" value="-12.9" spread="28.42"/>
                    <measurement group_id="O5" value="-11.0" spread="22.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP at Week 12</title>
        <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP at Week 12</title>
          <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.3" spread="25.56"/>
                    <measurement group_id="O2" value="-6.5" spread="14.05"/>
                    <measurement group_id="O3" value="-10.8" spread="17.27"/>
                    <measurement group_id="O4" value="-14.6" spread="25.22"/>
                    <measurement group_id="O5" value="-11.2" spread="21.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP at Week 16</title>
        <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP at Week 16</title>
          <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" spread="24.92"/>
                    <measurement group_id="O2" value="-5.5" spread="17.44"/>
                    <measurement group_id="O3" value="-10.8" spread="16.26"/>
                    <measurement group_id="O4" value="-12.5" spread="24.65"/>
                    <measurement group_id="O5" value="-10.7" spread="21.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP at Week 20</title>
        <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP at Week 20</title>
          <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="24.46"/>
                    <measurement group_id="O2" value="-6.4" spread="14.07"/>
                    <measurement group_id="O3" value="-10.3" spread="18.66"/>
                    <measurement group_id="O4" value="-11.6" spread="25.06"/>
                    <measurement group_id="O5" value="-10.1" spread="21.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP at Week 24</title>
        <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP at Week 24</title>
          <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" spread="23.41"/>
                    <measurement group_id="O2" value="-6.7" spread="13.93"/>
                    <measurement group_id="O3" value="-9.1" spread="17.96"/>
                    <measurement group_id="O4" value="-10.8" spread="27.79"/>
                    <measurement group_id="O5" value="-9.6" spread="21.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP at Week 28</title>
        <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP at Week 28</title>
          <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="48.65"/>
                    <measurement group_id="O2" value="-6.3" spread="17.24"/>
                    <measurement group_id="O3" value="-11.3" spread="18.37"/>
                    <measurement group_id="O4" value="-6.8" spread="26.24"/>
                    <measurement group_id="O5" value="-6.9" spread="30.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP at Week 32</title>
        <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP at Week 32</title>
          <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="26.15"/>
                    <measurement group_id="O2" value="-7.6" spread="14.59"/>
                    <measurement group_id="O3" value="-8.0" spread="20.16"/>
                    <measurement group_id="O4" value="-10.4" spread="26.24"/>
                    <measurement group_id="O5" value="-9.0" spread="22.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP at Week 36</title>
        <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP at Week 36</title>
          <description>For analysis purposes, all baseline are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="26.17"/>
                    <measurement group_id="O2" value="-6.0" spread="16.47"/>
                    <measurement group_id="O3" value="-8.7" spread="17.56"/>
                    <measurement group_id="O4" value="-9.0" spread="28.55"/>
                    <measurement group_id="O5" value="-8.1" spread="22.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score 28 (DAS28[hsCRP]) at Week 2</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score 28 (DAS28[hsCRP]) at Week 2</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.23"/>
                    <measurement group_id="O2" value="-1.5" spread="1.06"/>
                    <measurement group_id="O3" value="-1.8" spread="1.27"/>
                    <measurement group_id="O4" value="-1.7" spread="1.13"/>
                    <measurement group_id="O5" value="-1.6" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 (hsCRP) at Week 4</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 (hsCRP) at Week 4</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.20"/>
                    <measurement group_id="O2" value="-2.1" spread="1.37"/>
                    <measurement group_id="O3" value="-2.1" spread="1.26"/>
                    <measurement group_id="O4" value="-2.3" spread="1.20"/>
                    <measurement group_id="O5" value="-2.1" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 (hsCRP) at Week 6</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 (hsCRP) at Week 6</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.37"/>
                    <measurement group_id="O2" value="-2.2" spread="1.34"/>
                    <measurement group_id="O3" value="-2.5" spread="1.27"/>
                    <measurement group_id="O4" value="-2.4" spread="1.21"/>
                    <measurement group_id="O5" value="-2.4" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 (hsCRP) at Week 8</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 (hsCRP) at Week 8</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.29"/>
                    <measurement group_id="O2" value="-2.3" spread="1.25"/>
                    <measurement group_id="O3" value="-2.7" spread="1.30"/>
                    <measurement group_id="O4" value="-2.6" spread="1.32"/>
                    <measurement group_id="O5" value="-2.5" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 (hsCRP) at Week 12</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 (hsCRP) at Week 12</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="1.32"/>
                    <measurement group_id="O2" value="-2.3" spread="1.49"/>
                    <measurement group_id="O3" value="-2.8" spread="1.17"/>
                    <measurement group_id="O4" value="-2.7" spread="1.14"/>
                    <measurement group_id="O5" value="-2.6" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 (hsCRP) at Week 16</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 (hsCRP) at Week 16</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="1.21"/>
                    <measurement group_id="O2" value="-2.6" spread="1.54"/>
                    <measurement group_id="O3" value="-2.8" spread="1.19"/>
                    <measurement group_id="O4" value="-2.6" spread="0.92"/>
                    <measurement group_id="O5" value="-2.7" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 (hsCRP) at Week 20</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 (hsCRP) at Week 20</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="1.31"/>
                    <measurement group_id="O2" value="-2.8" spread="1.37"/>
                    <measurement group_id="O3" value="-2.7" spread="1.25"/>
                    <measurement group_id="O4" value="-2.8" spread="1.08"/>
                    <measurement group_id="O5" value="-2.7" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 (hsCRP) at Week 24</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 (hsCRP) at Week 24</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.26"/>
                    <measurement group_id="O2" value="-2.6" spread="1.47"/>
                    <measurement group_id="O3" value="-2.7" spread="1.41"/>
                    <measurement group_id="O4" value="-2.9" spread="1.14"/>
                    <measurement group_id="O5" value="-2.8" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 (hsCRP) at Week 28</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 (hsCRP) at Week 28</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.45"/>
                    <measurement group_id="O2" value="-2.7" spread="1.46"/>
                    <measurement group_id="O3" value="-2.9" spread="1.24"/>
                    <measurement group_id="O4" value="-2.9" spread="1.06"/>
                    <measurement group_id="O5" value="-2.7" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 (hsCRP) at Week 32</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 (hsCRP) at Week 32</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="1.44"/>
                    <measurement group_id="O2" value="-2.8" spread="1.45"/>
                    <measurement group_id="O3" value="-2.7" spread="1.17"/>
                    <measurement group_id="O4" value="-2.9" spread="1.25"/>
                    <measurement group_id="O5" value="-2.8" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 (hsCRP) at Week 36</title>
        <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 (hsCRP) at Week 36</title>
          <description>The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 to 10, with higher scores indicating more disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="1.45"/>
                    <measurement group_id="O2" value="-2.6" spread="1.48"/>
                    <measurement group_id="O3" value="-2.8" spread="1.22"/>
                    <measurement group_id="O4" value="-2.8" spread="1.32"/>
                    <measurement group_id="O5" value="-2.7" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 2</title>
        <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of Tender Joint Count 28 (TJC28) and Swollen Joint Count 28 (SJC28), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 2</title>
          <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of Tender Joint Count 28 (TJC28) and Swollen Joint Count 28 (SJC28), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.9" spread="15.74"/>
                    <measurement group_id="O2" value="-17.4" spread="13.45"/>
                    <measurement group_id="O3" value="-17.5" spread="14.61"/>
                    <measurement group_id="O4" value="-18.2" spread="14.96"/>
                    <measurement group_id="O5" value="-17.3" spread="14.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI at Week 4</title>
        <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI at Week 4</title>
          <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.3" spread="14.27"/>
                    <measurement group_id="O2" value="-24.6" spread="15.61"/>
                    <measurement group_id="O3" value="-22.1" spread="13.95"/>
                    <measurement group_id="O4" value="-24.3" spread="14.03"/>
                    <measurement group_id="O5" value="-22.7" spread="14.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI at Week 6</title>
        <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI at Week 6</title>
          <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.7" spread="14.64"/>
                    <measurement group_id="O2" value="-25.6" spread="14.71"/>
                    <measurement group_id="O3" value="-25.8" spread="13.10"/>
                    <measurement group_id="O4" value="-25.6" spread="13.83"/>
                    <measurement group_id="O5" value="-25.7" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI at Week 8</title>
        <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI at Week 8</title>
          <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.7" spread="13.68"/>
                    <measurement group_id="O2" value="-27.0" spread="13.69"/>
                    <measurement group_id="O3" value="-28.2" spread="12.66"/>
                    <measurement group_id="O4" value="-27.4" spread="13.92"/>
                    <measurement group_id="O5" value="-27.3" spread="13.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI at Week 12</title>
        <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI at Week 12</title>
          <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.4" spread="14.33"/>
                    <measurement group_id="O2" value="-27.2" spread="16.72"/>
                    <measurement group_id="O3" value="-29.7" spread="12.10"/>
                    <measurement group_id="O4" value="-28.8" spread="11.88"/>
                    <measurement group_id="O5" value="-28.5" spread="13.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI at Week 16</title>
        <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI at Week 16</title>
          <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" spread="13.07"/>
                    <measurement group_id="O2" value="-29.9" spread="16.04"/>
                    <measurement group_id="O3" value="-28.5" spread="12.11"/>
                    <measurement group_id="O4" value="-29.6" spread="10.03"/>
                    <measurement group_id="O5" value="-29.0" spread="12.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI at Week 20</title>
        <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI at Week 20</title>
          <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" spread="13.05"/>
                    <measurement group_id="O2" value="-31.8" spread="14.47"/>
                    <measurement group_id="O3" value="-28.2" spread="13.93"/>
                    <measurement group_id="O4" value="-31.1" spread="11.44"/>
                    <measurement group_id="O5" value="-29.7" spread="13.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI at Week 24</title>
        <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI at Week 24</title>
          <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.7" spread="13.81"/>
                    <measurement group_id="O2" value="-30.1" spread="15.05"/>
                    <measurement group_id="O3" value="-28.8" spread="14.09"/>
                    <measurement group_id="O4" value="-31.0" spread="13.15"/>
                    <measurement group_id="O5" value="-30.1" spread="13.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI at Week 28</title>
        <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI at Week 28</title>
          <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" spread="13.27"/>
                    <measurement group_id="O2" value="-31.4" spread="15.09"/>
                    <measurement group_id="O3" value="-29.8" spread="12.77"/>
                    <measurement group_id="O4" value="-32.7" spread="12.79"/>
                    <measurement group_id="O5" value="-30.4" spread="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI at Week 32</title>
        <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI at Week 32</title>
          <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" spread="15.08"/>
                    <measurement group_id="O2" value="-32.4" spread="14.63"/>
                    <measurement group_id="O3" value="-29.1" spread="13.40"/>
                    <measurement group_id="O4" value="-31.6" spread="15.08"/>
                    <measurement group_id="O5" value="-30.3" spread="14.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI at Week 36</title>
        <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI at Week 36</title>
          <description>CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. For analysis purposes, all baseline values are defined as the last measurement on or before the first dose of study drug in Study M12-963.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.6" spread="14.87"/>
                    <measurement group_id="O2" value="-30.9" spread="15.22"/>
                    <measurement group_id="O3" value="-30.0" spread="12.28"/>
                    <measurement group_id="O4" value="-30.9" spread="14.34"/>
                    <measurement group_id="O5" value="-29.8" spread="14.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Disease Activity (LDA) or Clinical Remission (CR) Response Rate Per DAS28 (hsCRP) at Week 2</title>
        <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>Low Disease Activity (LDA) or Clinical Remission (CR) Response Rate Per DAS28 (hsCRP) at Week 2</title>
          <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="5.0" upper_limit="26.6"/>
                    <measurement group_id="O2" value="8.1" lower_limit="2.1" upper_limit="22.0"/>
                    <measurement group_id="O3" value="28.2" lower_limit="16.4" upper_limit="43.9"/>
                    <measurement group_id="O4" value="25.6" lower_limit="14.4" upper_limit="41.2"/>
                    <measurement group_id="O5" value="18.7" lower_limit="13.3" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 4</title>
        <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 4</title>
          <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="19.0" upper_limit="46.1"/>
                    <measurement group_id="O2" value="32.4" lower_limit="19.5" upper_limit="48.6"/>
                    <measurement group_id="O3" value="30.8" lower_limit="18.5" upper_limit="46.5"/>
                    <measurement group_id="O4" value="45.0" lower_limit="30.7" upper_limit="60.2"/>
                    <measurement group_id="O5" value="34.8" lower_limit="27.8" upper_limit="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 6</title>
        <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 6</title>
          <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="31.2" upper_limit="60.1"/>
                    <measurement group_id="O2" value="24.3" lower_limit="13.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="43.6" lower_limit="29.3" upper_limit="59.0"/>
                    <measurement group_id="O4" value="50.0" lower_limit="35.2" upper_limit="64.8"/>
                    <measurement group_id="O5" value="41.1" lower_limit="33.8" upper_limit="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 8</title>
        <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 8</title>
          <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="31.2" upper_limit="60.1"/>
                    <measurement group_id="O2" value="27.0" lower_limit="15.2" upper_limit="43.1"/>
                    <measurement group_id="O3" value="53.8" lower_limit="38.6" upper_limit="68.4"/>
                    <measurement group_id="O4" value="55.0" lower_limit="39.8" upper_limit="69.3"/>
                    <measurement group_id="O5" value="45.6" lower_limit="38.0" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 12</title>
        <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 12</title>
          <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="35.5" upper_limit="64.5"/>
                    <measurement group_id="O2" value="35.1" lower_limit="21.8" upper_limit="51.3"/>
                    <measurement group_id="O3" value="56.4" lower_limit="41.0" upper_limit="70.7"/>
                    <measurement group_id="O4" value="52.5" lower_limit="37.5" upper_limit="67.1"/>
                    <measurement group_id="O5" value="48.7" lower_limit="41.1" upper_limit="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 16</title>
        <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 16</title>
          <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" lower_limit="36.5" upper_limit="65.7"/>
                    <measurement group_id="O2" value="52.8" lower_limit="37.0" upper_limit="68.0"/>
                    <measurement group_id="O3" value="62.2" lower_limit="46.1" upper_limit="76.0"/>
                    <measurement group_id="O4" value="48.7" lower_limit="33.9" upper_limit="63.8"/>
                    <measurement group_id="O5" value="53.6" lower_limit="45.7" upper_limit="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 20</title>
        <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 20</title>
          <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" lower_limit="39.9" upper_limit="68.8"/>
                    <measurement group_id="O2" value="55.6" lower_limit="39.6" upper_limit="70.5"/>
                    <measurement group_id="O3" value="56.4" lower_limit="41.0" upper_limit="70.7"/>
                    <measurement group_id="O4" value="60.0" lower_limit="44.6" upper_limit="73.7"/>
                    <measurement group_id="O5" value="56.7" lower_limit="48.9" upper_limit="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 24</title>
        <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 24</title>
          <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" lower_limit="46.8" upper_limit="75.0"/>
                    <measurement group_id="O2" value="44.4" lower_limit="29.5" upper_limit="60.4"/>
                    <measurement group_id="O3" value="56.4" lower_limit="41.0" upper_limit="70.7"/>
                    <measurement group_id="O4" value="60.0" lower_limit="44.6" upper_limit="73.7"/>
                    <measurement group_id="O5" value="56.1" lower_limit="48.2" upper_limit="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 28</title>
        <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 28</title>
          <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="33.4" upper_limit="62.3"/>
                    <measurement group_id="O2" value="41.7" lower_limit="27.1" upper_limit="57.8"/>
                    <measurement group_id="O3" value="56.4" lower_limit="41.0" upper_limit="70.7"/>
                    <measurement group_id="O4" value="55.0" lower_limit="39.8" upper_limit="69.3"/>
                    <measurement group_id="O5" value="50.3" lower_limit="42.6" upper_limit="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 32</title>
        <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 32</title>
          <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="37.7" upper_limit="66.6"/>
                    <measurement group_id="O2" value="52.8" lower_limit="37.0" upper_limit="68.0"/>
                    <measurement group_id="O3" value="61.5" lower_limit="45.9" upper_limit="75.1"/>
                    <measurement group_id="O4" value="60.0" lower_limit="44.6" upper_limit="73.7"/>
                    <measurement group_id="O5" value="56.7" lower_limit="48.9" upper_limit="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 36</title>
        <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per DAS28 (hsCRP) at Week 36</title>
          <description>Percentage of participants achieving LDA or CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" lower_limit="39.9" upper_limit="68.8"/>
                    <measurement group_id="O2" value="41.7" lower_limit="27.1" upper_limit="57.8"/>
                    <measurement group_id="O3" value="59.0" lower_limit="43.4" upper_limit="72.9"/>
                    <measurement group_id="O4" value="47.5" lower_limit="32.9" upper_limit="62.5"/>
                    <measurement group_id="O5" value="51.0" lower_limit="43.2" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per DAS28 (hsCRP) at Week 2</title>
        <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per DAS28 (hsCRP) at Week 2</title>
          <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.5" upper_limit="17.4"/>
                    <measurement group_id="O2" value="5.4" lower_limit="0.6" upper_limit="18.6"/>
                    <measurement group_id="O3" value="12.8" lower_limit="5.1" upper_limit="27.2"/>
                    <measurement group_id="O4" value="10.3" lower_limit="3.5" upper_limit="24.2"/>
                    <measurement group_id="O5" value="8.4" lower_limit="4.9" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per DAS28 (hsCRP) at Week 4</title>
        <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per DAS28 (hsCRP) at Week 4</title>
          <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="6.3" upper_limit="28.2"/>
                    <measurement group_id="O2" value="8.1" lower_limit="2.1" upper_limit="22.0"/>
                    <measurement group_id="O3" value="23.1" lower_limit="12.4" upper_limit="38.5"/>
                    <measurement group_id="O4" value="25.0" lower_limit="14.0" upper_limit="40.4"/>
                    <measurement group_id="O5" value="17.7" lower_limit="12.5" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per DAS28 (hsCRP) at Week 6</title>
        <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per DAS28 (hsCRP) at Week 6</title>
          <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="19.0" upper_limit="46.1"/>
                    <measurement group_id="O2" value="18.9" lower_limit="9.2" upper_limit="34.5"/>
                    <measurement group_id="O3" value="33.3" lower_limit="20.6" upper_limit="49.1"/>
                    <measurement group_id="O4" value="27.5" lower_limit="16.0" upper_limit="43.0"/>
                    <measurement group_id="O5" value="27.8" lower_limit="21.4" upper_limit="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per DAS28 (hsCRP) at Week 8</title>
        <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per DAS28 (hsCRP) at Week 8</title>
          <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="17.1" upper_limit="43.7"/>
                    <measurement group_id="O2" value="21.6" lower_limit="11.1" upper_limit="37.4"/>
                    <measurement group_id="O3" value="38.5" lower_limit="24.9" upper_limit="54.1"/>
                    <measurement group_id="O4" value="37.5" lower_limit="24.2" upper_limit="53.0"/>
                    <measurement group_id="O5" value="31.6" lower_limit="24.9" upper_limit="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per DAS28 (hsCRP) at Week 12</title>
        <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per DAS28 (hsCRP) at Week 12</title>
          <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="19.0" upper_limit="46.1"/>
                    <measurement group_id="O2" value="21.6" lower_limit="11.1" upper_limit="37.4"/>
                    <measurement group_id="O3" value="38.5" lower_limit="24.9" upper_limit="54.1"/>
                    <measurement group_id="O4" value="40.0" lower_limit="26.3" upper_limit="55.4"/>
                    <measurement group_id="O5" value="32.9" lower_limit="26.1" upper_limit="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per DAS28 (hsCRP) at Week 16</title>
        <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per DAS28 (hsCRP) at Week 16</title>
          <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="25.6" upper_limit="54.3"/>
                    <measurement group_id="O2" value="30.6" lower_limit="17.9" upper_limit="47.0"/>
                    <measurement group_id="O3" value="37.8" lower_limit="24.0" upper_limit="53.9"/>
                    <measurement group_id="O4" value="30.8" lower_limit="18.5" upper_limit="46.5"/>
                    <measurement group_id="O5" value="34.6" lower_limit="27.6" upper_limit="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per DAS28 (hsCRP) at Week 20</title>
        <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per DAS28 (hsCRP) at Week 20</title>
          <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="27.0" upper_limit="55.5"/>
                    <measurement group_id="O2" value="36.1" lower_limit="22.4" upper_limit="52.5"/>
                    <measurement group_id="O3" value="25.6" lower_limit="14.4" upper_limit="41.2"/>
                    <measurement group_id="O4" value="37.5" lower_limit="24.2" upper_limit="53.0"/>
                    <measurement group_id="O5" value="35.0" lower_limit="28.0" upper_limit="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per DAS28 (hsCRP) at Week 24</title>
        <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per DAS28 (hsCRP) at Week 24</title>
          <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="20.9" upper_limit="48.5"/>
                    <measurement group_id="O2" value="30.6" lower_limit="17.9" upper_limit="47.0"/>
                    <measurement group_id="O3" value="38.5" lower_limit="24.9" upper_limit="54.1"/>
                    <measurement group_id="O4" value="45.0" lower_limit="30.7" upper_limit="60.2"/>
                    <measurement group_id="O5" value="36.9" lower_limit="29.8" upper_limit="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per DAS28 (hsCRP) at Week 28</title>
        <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per DAS28 (hsCRP) at Week 28</title>
          <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="20.9" upper_limit="48.5"/>
                    <measurement group_id="O2" value="27.8" lower_limit="15.7" upper_limit="44.1"/>
                    <measurement group_id="O3" value="38.5" lower_limit="24.9" upper_limit="54.1"/>
                    <measurement group_id="O4" value="42.5" lower_limit="28.5" upper_limit="57.8"/>
                    <measurement group_id="O5" value="35.7" lower_limit="28.6" upper_limit="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per DAS28 (hsCRP) at Week 32</title>
        <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per DAS28 (hsCRP) at Week 32</title>
          <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="25.0" upper_limit="53.2"/>
                    <measurement group_id="O2" value="38.9" lower_limit="24.8" upper_limit="55.2"/>
                    <measurement group_id="O3" value="35.9" lower_limit="22.7" upper_limit="51.6"/>
                    <measurement group_id="O4" value="45.0" lower_limit="30.7" upper_limit="60.2"/>
                    <measurement group_id="O5" value="39.5" lower_limit="32.2" upper_limit="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per DAS28 (hsCRP) at Week 36</title>
        <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per DAS28 (hsCRP) at Week 36</title>
          <description>Percentage of participants achieving CR on the DAS28 (hsCRP). The DAS28 (hsCRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, hsCRP, and general health are included in the DAS28 (hsCRP) score. Scores range from 0 (no disease activity) to 10 (highest degree of disease activity). LDA was defined as a score from 2.6 to &lt; 3.2, and CR was defined as a score &lt; 2.6. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="25.0" upper_limit="53.2"/>
                    <measurement group_id="O2" value="19.4" lower_limit="9.4" upper_limit="35.3"/>
                    <measurement group_id="O3" value="43.6" lower_limit="29.3" upper_limit="59.0"/>
                    <measurement group_id="O4" value="37.5" lower_limit="24.2" upper_limit="53.0"/>
                    <measurement group_id="O5" value="35.0" lower_limit="28.0" upper_limit="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per CDAI at Week 2</title>
        <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per CDAI at Week 2</title>
          <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="1.9" upper_limit="21.0"/>
                    <measurement group_id="O2" value="5.4" lower_limit="0.6" upper_limit="18.6"/>
                    <measurement group_id="O3" value="12.8" lower_limit="5.1" upper_limit="27.2"/>
                    <measurement group_id="O4" value="15.4" lower_limit="6.9" upper_limit="30.1"/>
                    <measurement group_id="O5" value="10.4" lower_limit="6.4" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per CDAI at Week 4</title>
        <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per CDAI at Week 4</title>
          <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="13.3" upper_limit="38.7"/>
                    <measurement group_id="O2" value="21.6" lower_limit="11.1" upper_limit="37.4"/>
                    <measurement group_id="O3" value="23.1" lower_limit="12.4" upper_limit="38.5"/>
                    <measurement group_id="O4" value="35.0" lower_limit="22.1" upper_limit="50.5"/>
                    <measurement group_id="O5" value="25.9" lower_limit="19.7" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per CDAI at Week 6</title>
        <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per CDAI at Week 6</title>
          <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="27.0" upper_limit="55.5"/>
                    <measurement group_id="O2" value="21.6" lower_limit="11.1" upper_limit="37.4"/>
                    <measurement group_id="O3" value="43.6" lower_limit="29.3" upper_limit="59.0"/>
                    <measurement group_id="O4" value="45.0" lower_limit="30.7" upper_limit="60.2"/>
                    <measurement group_id="O5" value="38.0" lower_limit="30.8" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per CDAI at Week 8</title>
        <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per CDAI at Week 8</title>
          <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" lower_limit="22.9" upper_limit="50.9"/>
                    <measurement group_id="O2" value="27.0" lower_limit="15.2" upper_limit="43.1"/>
                    <measurement group_id="O3" value="46.2" lower_limit="31.6" upper_limit="61.4"/>
                    <measurement group_id="O4" value="47.5" lower_limit="32.9" upper_limit="62.5"/>
                    <measurement group_id="O5" value="39.2" lower_limit="32.0" upper_limit="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per CDAI at Week 12</title>
        <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per CDAI at Week 12</title>
          <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="27.0" upper_limit="55.5"/>
                    <measurement group_id="O2" value="37.8" lower_limit="24.0" upper_limit="53.9"/>
                    <measurement group_id="O3" value="46.2" lower_limit="31.6" upper_limit="61.4"/>
                    <measurement group_id="O4" value="50.0" lower_limit="35.2" upper_limit="64.8"/>
                    <measurement group_id="O5" value="43.7" lower_limit="36.2" upper_limit="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per CDAI at Week 16</title>
        <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per CDAI at Week 16</title>
          <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" lower_limit="32.9" upper_limit="62.5"/>
                    <measurement group_id="O2" value="45.7" lower_limit="30.5" upper_limit="61.8"/>
                    <measurement group_id="O3" value="55.6" lower_limit="39.6" upper_limit="70.5"/>
                    <measurement group_id="O4" value="50.0" lower_limit="34.8" upper_limit="65.2"/>
                    <measurement group_id="O5" value="49.7" lower_limit="41.7" upper_limit="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per CDAI at Week 20</title>
        <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per CDAI at Week 20</title>
          <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="33.4" upper_limit="62.3"/>
                    <measurement group_id="O2" value="45.7" lower_limit="30.5" upper_limit="61.8"/>
                    <measurement group_id="O3" value="36.8" lower_limit="23.3" upper_limit="52.8"/>
                    <measurement group_id="O4" value="56.4" lower_limit="41.0" upper_limit="70.7"/>
                    <measurement group_id="O5" value="46.8" lower_limit="39.0" upper_limit="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per CDAI at Week 24</title>
        <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per CDAI at Week 24</title>
          <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" lower_limit="39.9" upper_limit="68.8"/>
                    <measurement group_id="O2" value="44.4" lower_limit="29.5" upper_limit="60.4"/>
                    <measurement group_id="O3" value="43.6" lower_limit="29.3" upper_limit="59.0"/>
                    <measurement group_id="O4" value="60.0" lower_limit="44.6" upper_limit="73.7"/>
                    <measurement group_id="O5" value="51.0" lower_limit="43.2" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per CDAI at Week 28</title>
        <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per CDAI at Week 28</title>
          <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="33.4" upper_limit="62.3"/>
                    <measurement group_id="O2" value="44.4" lower_limit="29.5" upper_limit="60.4"/>
                    <measurement group_id="O3" value="48.7" lower_limit="33.9" upper_limit="63.8"/>
                    <measurement group_id="O4" value="60.0" lower_limit="44.6" upper_limit="73.7"/>
                    <measurement group_id="O5" value="50.3" lower_limit="42.6" upper_limit="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per CDAI at Week 32</title>
        <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per CDAI at Week 32</title>
          <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="29.1" upper_limit="57.8"/>
                    <measurement group_id="O2" value="55.6" lower_limit="39.6" upper_limit="70.5"/>
                    <measurement group_id="O3" value="51.3" lower_limit="36.2" upper_limit="66.1"/>
                    <measurement group_id="O4" value="60.0" lower_limit="44.6" upper_limit="73.7"/>
                    <measurement group_id="O5" value="52.2" lower_limit="44.5" upper_limit="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDA or CR Response Rate Per CDAI at Week 36</title>
        <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>LDA or CR Response Rate Per CDAI at Week 36</title>
          <description>Percentage of participants achieving LDA or CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="37.7" upper_limit="66.6"/>
                    <measurement group_id="O2" value="44.4" lower_limit="29.5" upper_limit="60.4"/>
                    <measurement group_id="O3" value="59.0" lower_limit="43.4" upper_limit="72.9"/>
                    <measurement group_id="O4" value="60.0" lower_limit="44.6" upper_limit="73.7"/>
                    <measurement group_id="O5" value="54.1" lower_limit="46.3" upper_limit="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per CDAI Criteria at Week 2</title>
        <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 2 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per CDAI Criteria at Week 2</title>
          <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="10.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O3" value="2.6" lower_limit="0.0" upper_limit="14.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="10.7"/>
                    <measurement group_id="O5" value="0.6" lower_limit="0.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per CDAI Criteria at Week 4</title>
        <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 4 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per CDAI Criteria at Week 4</title>
          <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.0" upper_limit="15.1"/>
                    <measurement group_id="O3" value="5.1" lower_limit="0.5" upper_limit="17.8"/>
                    <measurement group_id="O4" value="5.0" lower_limit="0.5" upper_limit="17.4"/>
                    <measurement group_id="O5" value="3.2" lower_limit="1.2" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per CDAI Criteria at Week 6</title>
        <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 6 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per CDAI Criteria at Week 6</title>
          <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.0" upper_limit="13.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O3" value="10.3" lower_limit="3.5" upper_limit="24.2"/>
                    <measurement group_id="O4" value="5.0" lower_limit="0.5" upper_limit="17.4"/>
                    <measurement group_id="O5" value="4.4" lower_limit="2.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per CDAI Criteria at Week 8</title>
        <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 8 of Study M12-963</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per CDAI Criteria at Week 8</title>
          <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="0.5" upper_limit="16.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O3" value="17.9" lower_limit="8.7" upper_limit="33.0"/>
                    <measurement group_id="O4" value="17.5" lower_limit="8.4" upper_limit="32.3"/>
                    <measurement group_id="O5" value="10.1" lower_limit="6.2" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per CDAI Criteria at Week 12</title>
        <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 12 of Study M12-963 (considered Week 0 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per CDAI Criteria at Week 12</title>
          <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="1.8" upper_limit="19.7"/>
                    <measurement group_id="O2" value="8.1" lower_limit="2.1" upper_limit="22.0"/>
                    <measurement group_id="O3" value="12.8" lower_limit="5.1" upper_limit="27.2"/>
                    <measurement group_id="O4" value="12.5" lower_limit="5.0" upper_limit="26.6"/>
                    <measurement group_id="O5" value="10.1" lower_limit="6.2" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per CDAI Criteria at Week 16</title>
        <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 16 (Week 4 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per CDAI Criteria at Week 16</title>
          <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="1.9" upper_limit="20.6"/>
                    <measurement group_id="O2" value="5.7" lower_limit="0.6" upper_limit="19.6"/>
                    <measurement group_id="O3" value="11.1" lower_limit="3.8" upper_limit="25.9"/>
                    <measurement group_id="O4" value="15.8" lower_limit="7.1" upper_limit="30.8"/>
                    <measurement group_id="O5" value="10.1" lower_limit="6.1" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per CDAI Criteria at Week 20</title>
        <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 20 (Week 8 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per CDAI Criteria at Week 20</title>
          <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="3.2" upper_limit="22.6"/>
                    <measurement group_id="O2" value="11.4" lower_limit="3.9" upper_limit="26.5"/>
                    <measurement group_id="O3" value="15.8" lower_limit="7.1" upper_limit="30.8"/>
                    <measurement group_id="O4" value="17.9" lower_limit="8.7" upper_limit="33.0"/>
                    <measurement group_id="O5" value="13.6" lower_limit="9.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per CDAI Criteria at Week 24</title>
        <description>Percentage of participants achieving CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 24 (Week 12 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per CDAI Criteria at Week 24</title>
          <description>Percentage of participants achieving CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="1.8" upper_limit="19.7"/>
                    <measurement group_id="O2" value="5.6" lower_limit="0.6" upper_limit="19.1"/>
                    <measurement group_id="O3" value="23.1" lower_limit="12.4" upper_limit="38.5"/>
                    <measurement group_id="O4" value="20.0" lower_limit="10.2" upper_limit="35.0"/>
                    <measurement group_id="O5" value="14.0" lower_limit="9.4" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per CDAI Criteria at Week 28</title>
        <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 28 (Week 16 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per CDAI Criteria at Week 28</title>
          <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="3.2" upper_limit="22.6"/>
                    <measurement group_id="O2" value="5.6" lower_limit="0.6" upper_limit="19.1"/>
                    <measurement group_id="O3" value="20.5" lower_limit="10.5" upper_limit="35.8"/>
                    <measurement group_id="O4" value="20.0" lower_limit="10.2" upper_limit="35.0"/>
                    <measurement group_id="O5" value="14.0" lower_limit="9.4" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per CDAI Criteria at Week 32</title>
        <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 32 (Week 20 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per CDAI Criteria at Week 32</title>
          <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="1.8" upper_limit="19.7"/>
                    <measurement group_id="O2" value="5.6" lower_limit="0.6" upper_limit="19.1"/>
                    <measurement group_id="O3" value="12.8" lower_limit="5.1" upper_limit="27.2"/>
                    <measurement group_id="O4" value="15.0" lower_limit="6.7" upper_limit="29.5"/>
                    <measurement group_id="O5" value="10.2" lower_limit="6.3" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR Response Rate Per CDAI Criteria at Week 36</title>
        <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
        <time_frame>Week 36 (Week 24 of Study M12-965)</time_frame>
        <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
            <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O2">
            <title>ABT-122 60 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O3">
            <title>ABT-122 120 mg EOW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O4">
            <title>ABT-122 120 mg EW / 120 mg EOW</title>
            <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
          </group>
          <group group_id="O5">
            <title>All ABT-122 120 mg EOW</title>
            <description>Open-label ABT-122 120 mg EOW.</description>
          </group>
        </group_list>
        <measure>
          <title>CR Response Rate Per CDAI Criteria at Week 36</title>
          <description>Percentage of participants achieving CR per CDAI criteria. The CDAI is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to  10; CR was defined as a score  2.8. Estimates of the 95% confidence interval of the response rates for each treatment group were calculated using the Agrestil-Coull method.</description>
          <population>Safety Analysis Set: all participants who received at least 1 dose of study medication in M12-965 and had an assessment. LOCF was used for missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="3.2" upper_limit="22.6"/>
                    <measurement group_id="O2" value="11.1" lower_limit="3.8" upper_limit="25.9"/>
                    <measurement group_id="O3" value="17.9" lower_limit="8.7" upper_limit="33.0"/>
                    <measurement group_id="O4" value="15.0" lower_limit="6.7" upper_limit="29.5"/>
                    <measurement group_id="O5" value="13.4" lower_limit="8.8" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Protocol-related treatment-emergent AEs (TEAEs) and treatment-emergent serious adverse events (TESAEs) were collected from the first dose of study drug in study M12-965 until 70 days after the last dose of study drug (up to 32 weeks).</time_frame>
      <desc>A protocol-related TEAE or TESAE is defined as any AE with onset or worsening reported by a participant from the first dose of study drug in study M12-965 until 70 days have elapsed following discontinuation of ABT-122 administration. Events were collected whether elicited or spontaneously reported by the participant.</desc>
      <group_list>
        <group group_id="E1">
          <title>ADA 40 mg EOW / ABT-122 120 mg EOW</title>
          <description>Double-blind ADA 40 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
        <group group_id="E2">
          <title>ABT-122 60 mg EOW / 120 mg EOW</title>
          <description>Double-blind ABT-122 60 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
        <group group_id="E3">
          <title>ABT-122 120 mg EOW / 120 mg EOW</title>
          <description>Double-blind ABT-122 120 mg EOW for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
        <group group_id="E4">
          <title>ABT-122 120 mg EW / 120 mg EOW</title>
          <description>Double-blind ABT-122 120 mg every week (EW) for 11 weeks. Open-label ABT-122 120 mg EOW.</description>
        </group>
        <group group_id="E5">
          <title>All ABT-122 120 mg EOW</title>
          <description>Open-label ABT-122 120 mg EOW.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>INFLAMMATION OF WOUND</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NODULE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>HEPATOBILIARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>FOOD ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ATYPICAL PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>HERPES VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>PARAMETRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>PULPITIS DENTAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>RASH PUSTULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CHEST INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>SKIN ABRASION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>BLOOD CHOLESTEROL INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>BLOOD SODIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>BLOOD TRIGLYCERIDES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>EOSINOPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>TENDON DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ADNEXA UTERI CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>NAIL DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>RASH VESICULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

